Nevertheless, functional t-dEV differences from IRF5-high and -low tumors were established in two distinctly different tumor types, providing the necessary support for focusing on IRF5-mediated immune protection and targeting immune escape at distant sites via loss of IRF5 expression/function. The gene discussed is IRF5; the disease is neoplasm.